Artwork

Inhalt bereitgestellt von Sasha High. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Sasha High oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Player FM - Podcast-App
Gehen Sie mit der App Player FM offline!

S2/E112. What's Coming in Obesity Medicine? The Med Pipeline with Dr. Sean Wharton

52:17
 
Teilen
 

Manage episode 422869155 series 3450393
Inhalt bereitgestellt von Sasha High. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Sasha High oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.

What new medications are coming down the pipeline in Obesity Medicine? I explore the latest and greatest in obesity pharmacotherapy with my guest today, Dr. Sean Wharton.

Dr. Wharton is one of the leading Canadian researchers in Obesity Medicine. He is co-lead author of the Canadian Obesity Guidelines and the primary author of many of the clinical trials in bariatric medicine and type 2 diabetes. We discussed what is being studied in Phase 2 and 3 clinical trials in obesity management including:

  • Semaglutide (Wegovy/Ozempic)
  • Tirzepatide (Mounjaro/Zepbound)
  • Retatrutide (GLP1, GIP, glucagon triple analogue)
  • Cagrisema (amylin/GLP1 dual analogue)
  • Bimagrumab (human monoclonal antibody)
  • Cannabinoid-receptor antagonists (CB1)
  • Orforglipron
  • Oral GLP1 peptides
  • Medications taken once monthly

**A small error that Dr. Wharton wanted to correct. The Amgen molecule discussed today is a GIPR antagonist, not a glucagon antagonist.

This week’s show brought to you by FRIDAY’S HEALTH.

If you’re in the USA looking for a healthcare provider and comprehensive obesity medicine program to support you in a science-backed, compassionate way, then check out Fridays Health. Each patient works with a medical provider as well as a team of coaches to pair medical treatment with effective behavioural support. Use code HIGH to get $20 USD off the first month of your membership.

https://www.joinfridays.com/

FIND DR. SEAN WHARTON

Instagram @drseanwharton

Clinical Trials https://whartonmedicalclinic.com/clinical-trials/

FOLLOW SASHA

Instagram - https://www.instagram.com/sashahighmd/

Tiktok - https://www.tiktok.com/@sashahighmd

WORK WITH ME

Join my Weight Loss Coaching Program for women, Best Weight https://www.sashahighmd.com/bestweight

Recover Strong for Binge Eating - https://www.sashahighmd.com/bed

Ontario OHIP-covered Obesity Medicine https://www.highmetabolicclinic.com

  continue reading

132 Episoden

Artwork
iconTeilen
 
Manage episode 422869155 series 3450393
Inhalt bereitgestellt von Sasha High. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Sasha High oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.

What new medications are coming down the pipeline in Obesity Medicine? I explore the latest and greatest in obesity pharmacotherapy with my guest today, Dr. Sean Wharton.

Dr. Wharton is one of the leading Canadian researchers in Obesity Medicine. He is co-lead author of the Canadian Obesity Guidelines and the primary author of many of the clinical trials in bariatric medicine and type 2 diabetes. We discussed what is being studied in Phase 2 and 3 clinical trials in obesity management including:

  • Semaglutide (Wegovy/Ozempic)
  • Tirzepatide (Mounjaro/Zepbound)
  • Retatrutide (GLP1, GIP, glucagon triple analogue)
  • Cagrisema (amylin/GLP1 dual analogue)
  • Bimagrumab (human monoclonal antibody)
  • Cannabinoid-receptor antagonists (CB1)
  • Orforglipron
  • Oral GLP1 peptides
  • Medications taken once monthly

**A small error that Dr. Wharton wanted to correct. The Amgen molecule discussed today is a GIPR antagonist, not a glucagon antagonist.

This week’s show brought to you by FRIDAY’S HEALTH.

If you’re in the USA looking for a healthcare provider and comprehensive obesity medicine program to support you in a science-backed, compassionate way, then check out Fridays Health. Each patient works with a medical provider as well as a team of coaches to pair medical treatment with effective behavioural support. Use code HIGH to get $20 USD off the first month of your membership.

https://www.joinfridays.com/

FIND DR. SEAN WHARTON

Instagram @drseanwharton

Clinical Trials https://whartonmedicalclinic.com/clinical-trials/

FOLLOW SASHA

Instagram - https://www.instagram.com/sashahighmd/

Tiktok - https://www.tiktok.com/@sashahighmd

WORK WITH ME

Join my Weight Loss Coaching Program for women, Best Weight https://www.sashahighmd.com/bestweight

Recover Strong for Binge Eating - https://www.sashahighmd.com/bed

Ontario OHIP-covered Obesity Medicine https://www.highmetabolicclinic.com

  continue reading

132 Episoden

All episodes

×
 
Loading …

Willkommen auf Player FM!

Player FM scannt gerade das Web nach Podcasts mit hoher Qualität, die du genießen kannst. Es ist die beste Podcast-App und funktioniert auf Android, iPhone und im Web. Melde dich an, um Abos geräteübergreifend zu synchronisieren.

 

Kurzanleitung